LSD1

LSD1製品

All (11)
LSD1阻害剤 (11)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S7680	SP2509	SP2509 (HCI-2509) is a selective histone demethylase LSD1 inhibitor with IC50 of 13 nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. SP2509 induces apoptosis and promotes autophagy.	Nat Commun, 2024, 15(1):5631 MedComm (2020), 2023, 4(3):e269 JCI Insight, 2023, 8(15)e167440
S7796	GSK2879552 2HCl	GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with K_i_app of 1.7 μM. Phase 1.	Nat Commun, 2024, 15(1):7366 Nat Commun, 2024, 15(1):5631 MedComm (2020), 2023, 4(3):e269
S7795	Iadademstat (ORY-1001) 2HCl	Iadademstat 2HCl (ORY-1001, RG-6016) is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of <20 nM, with high selectivity against related FAD dependent aminoxidases. Phase 1.	Nat Commun, 2024, 15(1):5631 Cell Death Discov, 2024, 10(1):166 Nat Cell Biol, 2023, 10.1038/s41556-023-01281-y
S7574	GSK-LSD1 2HCl	GSK-LSD1 2HCl is an irreversible, and selective LSD1 inhibitor with IC50 of 16 nM, > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B).	Nat Commun, 2024, 15(1):5631 Cell Death Dis, 2023, 10.1038/s41419-023-06238-5 Front Immunol, 2023,
S7237	OG-L002	OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM in a cell-free assay, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.	Cell Death Discov, 2024, 10(1):166 Viruses, 2023, 15(1)163 Sci Rep, 2021, 11(1):10285
S6722	Seclidemstat (SP-2577)	Seclidemstat (SP-2577) is a potent and orally bioavailable inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A) with IC50 of 13 nM. Seclidemstat (SP-2577) has potential antineoplastic activity.	Nat Commun, 2024, 15(1):5631 Nat Commun, 2023, 10.1038/s41467-023-42850-x
S9894^New	Vafidemstat	Vafidemstat(ORY-2001) is a potent, selective, brain-penetrant dual inhibitor of lysine-specific histone demethylase (LSD1, KDM1A) and MAO-B, with IC50 values of 105 nM and 58 nM, respectively. It shows potential for treating memory deficits and behavioral alterations in neurodegenerative and psychiatric diseases.
E4596^New	GSK-2879552	GSK-2879552 is a selective and potent inhibitor of Lysine-specific demethylase 1 (LSD1, KDM1A), with the potential to treat Small cell lung cancer (SCLC). It induces the expression of putative KDM1A target genes and demonstrates potent, predominantly cytostatic, antiproliferative activity in SCLC cell lines and tumor xenograft models.
S9734^New	Bomedemstat	Bomedemstat(IMG-7289) is an orally active and irreversible inhibitor of LSD1(lysine-specific demethylase 1). Bomedemstat exhibits the ability to enhance methylation levels of H3K4 and H3K9, subsequently leading to modifications in gene expression. Bomedemstat demonstrates anti-cancer properties by restraining cancer cell proliferation and prompting apoptosis.	Nat Commun, 2024, 15(1):7366
S0356	Pulrodemstat (CC-90011) besylate	Pulrodemstat (CC-90011) besylate (LSD1-IN-7 benzenesulfonate) is a potent and orally active lysine specific demethylase-1 (LSD1) inhibitor that is found to be effective in various tumors.	Nat Commun, 2024, 15(1):7366
S8438	T-3775440 HCl	T-3775440 HCl is an irreversible LSD1 inhibitor that is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nmol/L.	Cell Death Discov, 2024, 10(1):166
S7680	SP2509	SP2509 (HCI-2509) is a selective histone demethylase LSD1 inhibitor with IC50 of 13 nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. SP2509 induces apoptosis and promotes autophagy.	Nat Commun, 2024, 15(1):5631 MedComm (2020), 2023, 4(3):e269 JCI Insight, 2023, 8(15)e167440
S7796	GSK2879552 2HCl	GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with K_i_app of 1.7 μM. Phase 1.	Nat Commun, 2024, 15(1):7366 Nat Commun, 2024, 15(1):5631 MedComm (2020), 2023, 4(3):e269
S7795	Iadademstat (ORY-1001) 2HCl	Iadademstat 2HCl (ORY-1001, RG-6016) is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of <20 nM, with high selectivity against related FAD dependent aminoxidases. Phase 1.	Nat Commun, 2024, 15(1):5631 Cell Death Discov, 2024, 10(1):166 Nat Cell Biol, 2023, 10.1038/s41556-023-01281-y
S7574	GSK-LSD1 2HCl	GSK-LSD1 2HCl is an irreversible, and selective LSD1 inhibitor with IC50 of 16 nM, > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B).	Nat Commun, 2024, 15(1):5631 Cell Death Dis, 2023, 10.1038/s41419-023-06238-5 Front Immunol, 2023,
S7237	OG-L002	OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM in a cell-free assay, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively.	Cell Death Discov, 2024, 10(1):166 Viruses, 2023, 15(1)163 Sci Rep, 2021, 11(1):10285
S6722	Seclidemstat (SP-2577)	Seclidemstat (SP-2577) is a potent and orally bioavailable inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A) with IC50 of 13 nM. Seclidemstat (SP-2577) has potential antineoplastic activity.	Nat Commun, 2024, 15(1):5631 Nat Commun, 2023, 10.1038/s41467-023-42850-x
S9894^New	Vafidemstat	Vafidemstat(ORY-2001) is a potent, selective, brain-penetrant dual inhibitor of lysine-specific histone demethylase (LSD1, KDM1A) and MAO-B, with IC50 values of 105 nM and 58 nM, respectively. It shows potential for treating memory deficits and behavioral alterations in neurodegenerative and psychiatric diseases.
E4596^New	GSK-2879552	GSK-2879552 is a selective and potent inhibitor of Lysine-specific demethylase 1 (LSD1, KDM1A), with the potential to treat Small cell lung cancer (SCLC). It induces the expression of putative KDM1A target genes and demonstrates potent, predominantly cytostatic, antiproliferative activity in SCLC cell lines and tumor xenograft models.
S9734^New	Bomedemstat	Bomedemstat(IMG-7289) is an orally active and irreversible inhibitor of LSD1(lysine-specific demethylase 1). Bomedemstat exhibits the ability to enhance methylation levels of H3K4 and H3K9, subsequently leading to modifications in gene expression. Bomedemstat demonstrates anti-cancer properties by restraining cancer cell proliferation and prompting apoptosis.	Nat Commun, 2024, 15(1):7366
S0356	Pulrodemstat (CC-90011) besylate	Pulrodemstat (CC-90011) besylate (LSD1-IN-7 benzenesulfonate) is a potent and orally active lysine specific demethylase-1 (LSD1) inhibitor that is found to be effective in various tumors.	Nat Commun, 2024, 15(1):7366
S8438	T-3775440 HCl	T-3775440 HCl is an irreversible LSD1 inhibitor that is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nmol/L.	Cell Death Discov, 2024, 10(1):166
S9894^New	Vafidemstat	Vafidemstat(ORY-2001) is a potent, selective, brain-penetrant dual inhibitor of lysine-specific histone demethylase (LSD1, KDM1A) and MAO-B, with IC50 values of 105 nM and 58 nM, respectively. It shows potential for treating memory deficits and behavioral alterations in neurodegenerative and psychiatric diseases.
E4596^New	GSK-2879552	GSK-2879552 is a selective and potent inhibitor of Lysine-specific demethylase 1 (LSD1, KDM1A), with the potential to treat Small cell lung cancer (SCLC). It induces the expression of putative KDM1A target genes and demonstrates potent, predominantly cytostatic, antiproliferative activity in SCLC cell lines and tumor xenograft models.
S9734^New	Bomedemstat	Bomedemstat(IMG-7289) is an orally active and irreversible inhibitor of LSD1(lysine-specific demethylase 1). Bomedemstat exhibits the ability to enhance methylation levels of H3K4 and H3K9, subsequently leading to modifications in gene expression. Bomedemstat demonstrates anti-cancer properties by restraining cancer cell proliferation and prompting apoptosis.	Nat Commun, 2024, 15(1):7366

LSD1阻害剤の選択性比較

Tags: LSD1 inhibitor | LSD1 modulator | LSD1 chemical